Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005849 · ClinicalTrials.gov registry record · Phase 2

Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by University of Chicago.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target
10
Study locations

NCT00005849 is a Phase 2 study of Lung Cancer that has completed, run by University of Chicago. The registered enrollment target is 15 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005849, a Phase 2 study of Lung Cancer, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target
10
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 plus paclitaxel in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.

Conditions Studied

Lung Cancer

Interventions

  • DRUG paclitaxel
  • DRUG bryostatin 1

Study Locations (10)

Illinois

  • University of Illinois at Chicago - Chicago
  • University of Chicago Cancer Research Center - Chicago
  • Louis A. Weiss Memorial Hospital - Chicago
  • Decatur Memorial Hospital Cancer Care Institute - Decatur
  • Evanston Northwestern Health Care - Evanston
  • Lutheran General Cancer Care Center - Park Ridge
  • Oncology/Hematology Associates of Central Illinois, P.C. - Peoria
  • Central Illinois Hematology Oncology Center - Springfield

Indiana

  • Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
  • Michiana Hematology/Oncology P.C. - South Bend

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2000-04
Est. Completion 2003-11
Phase Phase 2

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00005849

The ClinicalTrials.gov registry entry for NCT00005849 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.

NCT00005849 reports 10 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Indiana.

Frequently Asked Questions

What is clinical trial NCT00005849 about?

NCT00005849 is a clinical study titled "Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 plus paclitaxel in treating patients who have stage IIIB...

What is the current status of trial NCT00005849?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2000-04. Estimated completion is 2003-11.

What conditions does trial NCT00005849 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00005849?

The interventions under investigation include: paclitaxel (DRUG), bryostatin 1 (DRUG).

Who is sponsoring clinical trial NCT00005849?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005849 being conducted?

This trial has 10 study locations across Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.